* Cytel Corp., of San Diego, announced a notice of allowance for apatent application covering core technology for its enzymaticsynthesis process for manufacturing of complex carbohydrates. Thetechnology from The Scripps Research Institute lowers productioncost by in situ generation of nucleotide-sugars.
* Cytoclonal Pharmaceutics Inc., of Dallas, said the U.S. patentoffice allowed the major claims for a pending patent covering theLCG gene, which is being developed for the diagnosis, imaging andtreatment of a class of lung cancer.
* Enzon Inc., of Piscataway, N.J., received two additional patents forits hemoglobin-based oxygen carrier, PEG-hemoglobin. Patent No.5,478,806 covers tumor radiosensitization and No. 5,478,805 coversa method of fractionating and purifying PEG-hemoglobin conjugates.
* Immunomedics Inc., of Morris Plains, N.J., was issued U.S. patentNo. 5,482,698, which has 43 claims covering pretargeting methodsfor detecting and treating cancerous, infectious and cardiovascularlesions.
* InSite Vision Inc., of Alameda, Calif., said U.S. patent No.5,474,985 covering novel uses of topical non-steroidal anti-inflammatory drugs in the eye was issued. InSite licensed the patentfrom the University of California.
* Matritech Inc., of Newton, Mass., received a notice of allowance onits patent application relating to the discovery of certain nuclearmatrix proteins as highly accurate markers for colon cancer.
* Metabolix Inc., of Cambridge, Mass., was awarded U.S. patent No.5,480,794 describing the production of PHA synthase enzymes intransgenic bacteria, yeast, fungi and plant crops.
* Ophidian Pharmaceuticals Inc., of Madison, Wis., was granted U.S.patent No. 5,466,672 covering the therapeutic use of clostridiumdifficile toxin A for gastrointestinal cancers.
* Osiris Therapeutics Inc., of Baltimore, was granted U.S. patent No.5,489,359 containing broad claims to the composition of matter forhuman mesenchymal stem cells and to their therapeutic compositions.
* Prizm Pharmaceuticals Inc., of San Diego, received notice ofallowance that a patent for DNA-encoding recombinant saporin wasallowed. Saporin is an enzyme that inhibits protein synthesis resultingin cell death, the company said.
* Sepracor Inc., of Marlborough, Mass., was granted U.S. patent No.5,474,997 claiming pharmaceutical compositions containing (2R,4S)-itraconazole and a method for treating fungal and yeastinfections.
* Synaptic Pharmaceutical Corp., of Paramus, N.J., was awarded twomore U.S. patents for serotonin receptor genes, bringing to five itspatents in that area. The new patents cover the genes for serotonin-4(No. 5,472,866) and serotonin-1E (No. 5,476,782) receptors andtheir use for drug discovery and development.
* Synsorb Biotech Inc., of Calgary, Alberta, was awarded U.S. patentNo. 5,484,773 covering the use of its technology for the treatment ofgastroenteric conditions.
* Xoma Corp., of Berkeley, Calif., was issued U.S. patent No.5,484,704 covering a diagnostic assay for measuring levels oflipopolysaccharide binding protein in human blood.
* Zynaxis Inc., of Malvern, Pa., was awarded patents covering theuse of Zyn-Linker molecules to deliver drugs to reduce unwantedcellular adhesions, and covering nasal delivery of vaccines toimmunize against certain types of respiratory viruses.
(c) 1997 American Health Consultants. All rights reserved.